Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimivalimab - Concentra Biosciences

Next Previous
Search
Drug Profile

Pimivalimab - Concentra Biosciences

Alternative Names: JTX-4014

Latest Information Update: 13 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jounce Therapeutics
  • Developer Concentra Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 31 May 2024 Updated efficacy and adverse events data from the phase I/II INNATE trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 25 Apr 2024 Jounce Therapeutics terminates enrolment in phase II SELECT trial for Non-small cell lung cancer (Second line therapy or greater, Combination therapy) in Georgia, Latvia, Moldova, Ukraine, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Hungary, Romania, Russia, Serbia, Slovakia, Turkey (NCT04549025)
  • 28 Nov 2023 Jounce Therapeutics completes the phase-I/II INNATE trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, In adults, In the elderly) in USA (IV, Infusion) (NCT04669899)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top